“Our contention is that Ligand’s (LGND -6.2%) shots are not so sure of the net as the Street would have it,” says Grant’s Interest Rate Observer in its latest issue.
Declining revenues could be in play after 2021 as the company’s top treatments will face tougher competition, and the majority of new products under development are a decade away from commercialization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.